OpenLegislation

Paragraph 10 F1

(1)

A cannabis-based product for medicinal use in humans.

(2)

A product which is—

(a)

specified in Part 1 as a consequence of the application of paragraphs 2 to 5 to a preparation or other product (not being the substance specified in paragraph 9) which is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers); and

(b)

produced for medicinal use in humans.

(3)

In this paragraph—

  • “cannabis-based product for medicinal use in humans” means a preparation or other product (not being the substance specified in paragraph 9), which—

    1. (a)

      is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);

    2. (b)

      is produced for medicinal use in humans; and

    3. (c)

      is—

      1. (i)

        a medicinal product, or

      2. (ii)

        a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product; and

  • “medicinal product” has the same meaning as in the Human Medicines Regulations 2012.

(4)

In this Schedule, “dronabinol” does not include any substance which—

(a)

has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and

(b)

is derived from cannabis, cannabis resin or their constituents,

and stereoisomers of dronabinol are to be construed accordingly.

Annotations

Textual amendments

F1

Sch. 1 para. 10 inserted (1.11.2018) by The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (S.I. 2018/1055), regs. 1(1), 9(3)